Page 146 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

144
Chapter 7
42. Dahan A, Dunne A, Swartjes M, et al. ARA 290 Improves Symptoms in Patients with Sarcoidosis- Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. Mol Med. 2013;19(1):334-345. doi:10.2119/molmed.2013.00122
43. Yarnitsky D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain. 2015;156 Suppl(2):S24-31. doi:10.1097/01.j.pain.0000460343.46847.58
44. Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017:10.1212/WNL.0000000000003760. doi:10.1212/ WNL.0000000000003760
45. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13(9):924-935. doi:10.1016/S1474-4422(14)70102-4
46. Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ. Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. Neuropsychopharmacology. 2018;43(4):739-750. doi:10.1038/npp.2017.205
47. Leroux E, Beaudet L, Boudreau G, et al. A Nursing Intervention Increases Quality of Life and Self-Efficacy in Migraine: A 1-Year Prospective Controlled Trial. Headache J Head Face Pain. 2018;58(2):260-274. doi:10.1111/head.13178
48. Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2017;37(12):1115-1125. doi:10.1177/0333102416660549
49. Carlsen LN, Westergaard ML, Bisgaard M, Schytz JB, Jensen RH. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018;38(7):1316-1325. doi:10.1177/0333102417736898
50. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart J-A. Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012;153(1):56-61. doi:10.1016/j.pain.2011.08.018
51. Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37. doi:10.1186/ s10194-017-0742-1
52. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KMA. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology. 2003;60(8):1308-1312. doi:10.1212/01. WNL.0000058907.41080.54
53. Stam AH, De Vries B, Janssens ACJW, et al. Shared genetic factors in migraine and depression: Evidence from a genetic isolate. Neurology. 2010;74(4):288-294. doi:10.1212/WNL.0b013e3181cbcd19
54. Schur EA, Noonan C, Buchwald D, Goldberg J, Afari N. A Twin Study of Depression and Migraine: Evidence for a Shared Genetic Vulnerability. Headache J Head Face Pain. 2009;49(10):1493-1502. doi:10.1111/j.1526-4610.2009.01425.x
55. Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. Science (80- ). 2018;360(6395):eaap8757. doi:10.1126/science.aap8757
56. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication- overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014;34(9):645- 655. doi:10.1177/0333102414521508
57. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-1745. doi:10.1001/ jama.2012.505
58. Herd C, Tomlinson C, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Chochrane Syst Rev. 2018;(6). doi:10.1002/14651858.CD011616.pub2.www.cochranelibrary.com
59. Wollmer MA, De Boer C, Kalak N, et al. Facing depression with botulinum toxin: A randomized controlled trial. J Psychiatr Res. 2012;46(5):574-581. doi:10.1016/j.jpsychires.2012.01.027
60. Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(6):555-565. doi:10.1016/S1474-4422(16)00017-X
61. Durand PD, Couto RA, Isakov R, et al. Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect. Aesthetic Surg J. 2016:sjv208. doi:10.1093/asj/sjv208